Gene Expression Profiling
In recent years, gene expression profiling has revealed that Muscle Invasive Bladder Cancer (MIBC) is a heterogeneous disease; like breast cancer, it can be stratified into different molecular subtypes. Read more
Diagnosis and prognosis of urothelial cancer are performed via assessment of specific tissue and cellular features by pathologists. Importantly, intra and inter variability of pathologists can affect diagnosis. There is a need to develop methods for reducing the inconsistency of pathologic assessment.
In this project we are investigating the molecular characteristics of BCG-resistant HR-NMIBC, identifying key differences that drive resistance and progression, and testing drugs targeting these alterations as personalized alternative treatments in organoids.
Tumor Organoid Models
For primary diagnosis, bladder cancer patients are treated by surgical resection of the tumor and may require additional treatment depending on tumor stage. Read more
Upper Tract Urothelial Carcinoma
Our research on urothelial carcinoma of the upper urinary tract (UTUC) mainly focusses on the bladder recurrences following surgery for this disease. Read more
Mechanisms of BCG resistance
Patients with high-risk non-muscle invasive bladder cancer are treated with intravesical BCG immunotherapy, which facilitates removal of residual tumor cells after transurethral bladder tumor resection. Read more
Joep J. de Jong
Mathijs Scholtes MD
Christiaan de Jong
Thomas van Doeveren